Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 119Thoracic 46Gynecologic 42Breast 32CNS 15Genitourinary 10Tumor-Agnostic 5Sarcoma 2Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Rectal Neoplasms 1Neutropenia 1Neoplasms 1Fever 1Febrile Neutropenia 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13Cytarabine 9Dalteparin 8Rivaroxaban 7Daunorubicin 7apixaban 6Etoposide 6Methotrexate 5Idarubicin 5Heparin, Low-Molecular-Weight 5Cyclophosphamide 5emicizumab 4Tinzaparin 4Thioguanine 4Mitoxantrone 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Enoxaparin 4pegfilgrastim 3hetrombopag 3epoetin beta 3Saline Solution 3Radiotherapy 3Hydrocortisone 3Erythropoietin 3Dexamethasone 3Aspirin 3Asparaginase 3telapristone acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Bevacizumab × Classical hematology × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡